The overall objective of the Clinical Laboratory Core will be to provide support for all laboratory needs of the clinical trials described in Projects 1 and 2 of this Program Project. This will include the collection of biological specimens from study participants, facilitating clinical laboratory testing needed for patient management and assessment of drug safety and tolerability, routine storage of biological samples for future use, malaria specific laboratory testing from blood specimens, and the collection and process of placental samples including histopathology. The clinical laboratory core will also be responsible for supporting the collection of biological samples for the immunology studies described in Project 3 ofthe Program Project. Performance sites will include a phlebotomy center and clinical laboratory within our study clinic located on the Tororo District Hospital (TDH) campus, a placental histopathology laboratory located near our study clinic on the TDH campus, and the Joint Clinical Research Center (JCRC) referral laboratory where clinical laboratory testing will be performed. The specific objectives oithe Clinical Laboratory Core will be as follows: Objective 1: To collect, transport and store all biological specimens from study participants. Objective 2: To perform all malaria diagnostic testing. Malaria microscopy will be performed by experienced technicians including double reading of blood smears for quality control purposes. Malaria microscopy results will be available in real time for patient management. A PCR based assay will be available for the detection of asymptomatic parasitemia using dried blood spots collected on filter paper. Objective 3: To collect placental specimens and perform histopathology studies. The gold standard for classification of placental malaria is based on histopathological assessment of placental tissue collected at the time of birth. Our research center has established local capacity for the collection, processing, and staining of histopathology specimens for the diagnosis of placental malaria, one of the primary outcome measures for the studies outlined in this Program Project.

Public Health Relevance

The success of the proposed Program Project, which includes two randomized clinical trials and supporting immunology studies, requires a strong Clinical Laboratory Core that includes proper collection of biological specimens, transport of specimens to our reference laboratory, and performance of on-site laboratory testing to ensure that study participants are managed properly and study outcomes accurately assessed.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Program Projects (P01)
Project #
5P01HD059454-07
Application #
8706924
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
7
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Wallender, Erika; Vucicevic, Katarina; Jagannathan, Prasanna et al. (2018) Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. J Infect Dis 217:964-972
Odorizzi, Pamela M; Jagannathan, Prasanna; McIntyre, Tara I et al. (2018) In utero priming of highly functional effector T cell responses to human malaria. Sci Transl Med 10:
Savic, Rada M; Jagannathan, Prasanna; Kajubi, Richard et al. (2018) Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Clin Infect Dis 67:1079-1088
Jagannathan, Prasanna; Kakuru, Abel; Okiring, Jaffer et al. (2018) Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial. PLoS Med 15:e1002606
Jagannathan, Prasanna; Kajubi, Richard; Aweeka, Francesca T (2018) Response to ""Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction"". Clin Pharmacol Ther 103:571
Prahl, Mary; Jagannathan, Prasanna; McIntyre, Tara I et al. (2017) Sex Disparity in Cord Blood FoxP3+ CD4 T Regulatory Cells in Infants Exposed to Malaria In Utero. Open Forum Infect Dis 4:ofx022
Sonoiki, Ebere; Nsanzabana, Christian; Legac, Jennifer et al. (2017) Altered Plasmodium falciparum Sensitivity to the Antiretroviral Protease Inhibitor Lopinavir Associated with Polymorphisms in pfmdr1. Antimicrob Agents Chemother 61:
Kajubi, R; Huang, L; Jagannathan, P et al. (2017) Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention. Clin Pharmacol Ther 102:520-528
Natureeba, Paul; Kakuru, Abel; Muhindo, Mary et al. (2017) Intermittent Preventive Treatment With Dihydroartemisinin-Piperaquine for the Prevention of Malaria Among HIV-Infected Pregnant Women. J Infect Dis 216:29-35
Roh, Michelle E; Shiboski, Stephen; Natureeba, Paul et al. (2017) Protective Effect of Indoor Residual Spraying of Insecticide on Preterm Birth Among Pregnant Women With HIV Infection in Uganda: A Secondary Data Analysis. J Infect Dis 216:1541-1549

Showing the most recent 10 out of 59 publications